Abstract 165P
Background
The role of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) as an immune checkpoint has garnered significant interest in oncology, particularly in the context of non-small cell lung cancer (NSCLC). TIGIT inhibition represents a promising therapeutic strategy, potentially enhancing anti-tumor immunity. This meta-analysis aims to evaluate the clinical efficacy of TIGIT inhibitors in NSCLC and to explore the correlation between TIGIT expression and relevant biomarkers.
Methods
A comprehensive literature search was conducted in databases such as PubMed, Scopus, and clinical trial registries up to June 2024. Studies were included if they reported clinical outcomes of TIGIT inhibitors in NSCLC patients. Data extraction focused on progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety profiles. Biomarker correlation analysis included TIGIT expression levels, PD-L1 status, and other immune-related markers. Statistical analysis involved pooled hazard ratios (HRs) for PFS and OS, and odds ratios (ORs) for ORR, with 95% confidence intervals (CIs).
Results
A total of 12 studies encompassing 1,750 patients were included. TIGIT inhibition showed a significant improvement in PFS (HR 0.73, 95% CI 0.61-0.87) and OS (HR 0.78, 95% CI 0.66-0.92) compared to standard treatments. The ORR was notably higher in the TIGIT inhibitor group (OR 1.45, 95% CI 1.21-1.73). Biomarker analysis revealed a positive correlation between high TIGIT expression and enhanced response rates. Additionally, patients with concurrent high PD-L1 expression demonstrated a synergistic benefit from TIGIT inhibition. The safety profile of TIGIT inhibitors was manageable, with no unexpected adverse events.
Conclusions
TIGIT inhibition offers a significant therapeutic benefit in NSCLC, improving survival outcomes and response rates. The correlation between TIGIT expression and clinical efficacy underscores the potential for biomarker-driven patient selection. These findings support further investigation and development of TIGIT inhibitors as a component of NSCLC treatment regimens.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session
Resources:
Abstract
156P - Liver Metastases Correlate with Shortened Survival and Increased Dissociate Response in Patients Treated with T-Cell Engagers.
Presenter: Noé Herbel
Session: Poster Display session
Resources:
Abstract
157P - Preliminary results of a multicentric randomized phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)
Presenter: Caroline Even
Session: Poster Display session
Resources:
Abstract
158P - XCR1+ dendritic cell (DC) role in antitumoral response to anti PD-L1 antibody: Data from the phase Ib/II trial of DC vaccination in small cell lung cancer patients
Presenter: Maria Gonzalez Cao
Session: Poster Display session
Resources:
Abstract
159P - Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
Presenter: Giada Sabatino
Session: Poster Display session
Resources:
Abstract
160P - Oral DNA vaccination targeting personalised neoantigens in immune checkpoint-inhibitor treated solid tumor patients: Interim results
Presenter: Domas Vaitiekus
Session: Poster Display session
Resources:
Abstract
161P - Safety of TrimelVax vaccine for patients with advanced melanoma: Clinical results
Presenter: ROBERTO ESTAY
Session: Poster Display session
Resources:
Abstract
162P - EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
Presenter: Romain Cohen
Session: Poster Display session
Resources:
Abstract
163P - Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
Presenter: Elise Jirovec
Session: Poster Display session
Resources:
Abstract
164P - Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract